Erkan Kaba

Erkan Kaba

Auto-generated profile, based on publicly available information

Erkan Kaba

Department of Thoracic Surgery, Istanbul Bilim University Medical Faculty, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Annals of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
PDF file
EKErkan Kaba
Erkan Kaba
BOBerker Ozkan
Berker Ozkan
SESuat Erus
Suat Erus
SDSalih Duman
Salih Duman
BCBerk Cimenoglu
Berk Cimenoglu
ATAlper Toker
Alper Toker
Purpose: To analyze the role of surgery in patients with Masaoka stage IVa thymoma treated with multimodality therapy.Methods: Of 191 patients undergoing surgery for thymoma in our department between January 2002 and December 2015, 39 (20.4%) had Masaoka stage IVa. Histopathological tumor type, myasthenic status of the Osserman–Genkins score, Masaoka stage at the first surgery, neoadjuvant treatment, number and type of surgeries, and survival rates were recorded.Results: Thymoma B2 was the most common histopathological tumor type (n = 16, 41%). Twenty-six (66.7%) patients underwent primary surgeries for Masaoka stage IVa thymoma, whereas nine (23.1%) underwent secondary surgeries and four (10.3%) underwent tertiary surgeries for pleural or pericardial recurrences. Median survival was 132 ± 25 (82–181; 95% confidence interval [CI]) months. Overall 3-, 5-, and 10-year survival rates were 93%, 93%, and 56%, respectively.Conclusion: Surgical treatment should be considered as a completion modality to oncological therapy and has the potential to provide long-term survival of Masaoka stage IVa in patients with thymoma. The type of surgery should be determined based on the invasiveness of the lesion.

22 January 2018 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
EKErkan Kaba
Erkan Kaba
MOMehmet Oguzhan Ozyurtkan
Mehmet Oguzhan Ozyurtkan
KAKemal Ayalp
Kemal Ayalp
TCTugba Cosgun
Tugba Cosgun
MAMazen Rasmi Alomari
Mazen Rasmi Alomari
ATAlper Toker
Alper Toker
To investigate the feasibility and efficacy of salvage lung resection and describe the possible indications and contraindications in patients with primary lung cancer. Thirty patients undergoing anatomical salvage lung resection were classified into three groups: GI, patients with progressive lung tumor despite definitive chemo- and/or radiotherapy; GII, patients who underwent emergency resection; and GIII, patients in whom neoadjuvant or definitive chemo- and/or radiotherapy was contraindicated because of severe comorbidities. The groups were compared based on, peri- and postoperative factors, and survival rates. The morbidity rate was 70%. Revision surgery was required in 23% of patients. Morbidity was affected by lower hematocrit and hemoglobin levels (P = 0.05). Mean hospital stay was 11 ± 4 days, which was longer in patients in whom complications developed (P = 0.0003). The in-hospital or 30-day mortality rate was 3%. Mean relapse-free survival and overall survivals were 14 ± 12 and 19 ± 13 months. Patients with progression of the persistent primary tumor after definitive chemo- and/or radiotherapy can undergo salvage lung resection with acceptable mortality and high morbidity rates, if the tumor is considered resectable. Other indications may be considered for salvage lung resection based on each patient’s specific evaluation.

1 June 2022 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
ATAlper Toker
Alper Toker
JHJ.W. Awori Hayanga
J.W. Awori Hayanga
ADAnkit Dhamija
Ankit Dhamija
EKErkan Kaba
Erkan Kaba
BOBerker Ozkan
Berker Ozkan
GAGhulam Husain Abbas
Ghulam Husain Abbas

1 March 2019 in Annals of Cardiothoracic Surgery
Verified
Journal Article
Closed access
PDF file
EKErkan Kaba
Erkan Kaba
TCTugba Cosgun
Tugba Cosgun
KAKemal Ayalp
Kemal Ayalp
ATAlper Toker
Alper Toker
Robotic thymectomy for myasthenia gravis

30 September 2019 in Tuberk Toraks
Verified
Journal Article
Closed access
NONeslihan OZCELIK
Neslihan OZCELIK
NANimet Aksel
Nimet Aksel
YBYılmaz Bülbül
Yılmaz Bülbül
YEYurnadur Erdoğan
Yurnadur Erdoğan
FGFiliz Güldaval
Filiz Güldaval
TÖTevfik Özlü
Tevfik Özlü
The results of standard chemotherapy in lung cancer are not very satisfactory, so it is important to identify genetic mutations that provide targeted therapies. Recent reports have suggested influences of racial difference on the frequency of mutation in lung cancer. We aimed to determine the frequency and regional distribution of genetic mutations of non-small cell lung cancer (NSCLC) in Turkey. Regional distribution of genetic mutations in lung cancer in Turkey (REDIGMA) study was carried out as a prospective, cross-sectional, observational study in a large number of centers in which lung cancer patients were followed and could perform genetic mutation analysis on patients' biopsy materials. The 703 patients (77.7% male, mean age 63.3 ± 12.5 years) who were diagnosed as NSCLC from 25 different centers were included in the study. Tumor samples from patients were reported as 87.1% adenocarcinoma, 6.4% squamous cell carcinoma and 6.5% other. Mutation tests were found to be positive in 18.9% of these patients. The mutations were 69.9% EGFR, 26.3% ALK, 1.6% ROS and 2.2% PDL. Mutations were higher in women and non-smokers (p<0.000, p<0.001). Again, the frequency of mutations in adenocarcinoma was higher in metastatic disease. There was no difference between the patient's age, area of residence, comorbidity and clinical stage and mutation frequency. Our study revealed that the EGFR mutation rate in Turkey with NSCLC was similar to East European, African-American and Caucasian patients, and was lower than in East Asia.